Risks from unexpected adverse reactions and product liability
First written in FY2020. 3 of 5 entries say "Restated". Latest entry: 2026-09-09.
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
9 other companies' latest entry also says "Mitigated".
- 2026-09-09MitigatedFinancial results presentation
「Safety: No safety concerns related to Redasemtide were identified in either trial, and good tolerability was confirmed.」
No new safety concerns were identified in either of the 2 trials covered, and good tolerability was confirmed. - FY2025RestatedAnnual report
「Medicines may produce unexpected adverse effects from the clinical-trial stage through and after commercial launch.」
The risks of unexpected adverse effects and product liability from the clinical trial stage through post-launch have been reconfirmed. - FY2024RestatedAnnual report
「Medicines may produce unexpected adverse effects from the clinical-trial stage through and after commercial launch.」
The risks of unexpected adverse effects and product liability from the clinical trial stage through post-launch have been reconfirmed. - FY2022RestatedAnnual report
「Medicines may produce unexpected adverse effects from the clinical-trial stage through and after commercial launch.」
The risks of unexpected adverse effects and product liability from the clinical trial stage through post-launch have been reconfirmed. - FY2020First statedAnnual report
「Medicines may produce unexpected adverse effects from the clinical-trial stage through and after commercial launch.」
Unexpected adverse effects from the clinical trial stage through post-launch, claims for damages, and impacts on public trust are described as risks.